Insider transactions

EDGAR

AEON Biopharma, Inc.

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.

A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.

Window: transactions dated on or after 2025-11-16.

Open-market purchases (code P)
1 transactions, 1,150,000 shares
Sum of shares × price per share: 243,455
Open-market sales (code S)
0 transactions, — shares

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

Showing 1–17 of 17

Insider transactions, newest first, as filed on SEC Forms 3, 4 and 5
DateReporting ownerCodeAcquired or disposedSharesPrice per share, as filedValue (derived)Shares owned afterDirect or indirectRule 10b5-1 boxNotesSource
2026-10-30 Filed 2026-11-10Daewoong Co., Ltd 10% owner
X

Exercise of in-the-money or at-the-money derivative security

Class A Common Stock, $0.0001 par value per share
Acquired (A)11,236,6310.0001
1,123.6631

Derived: shares × price per share. Exact value 1123.6631.

23,188,345Indirect (I) By Daewoong Pharmaceutical Co., Ltd.No
F2, F1
  • F2 On October 30, 2026 (the Exercise Date), DWP exercised in full, on a cashless basis pursuant to Section 10 of the Pre-Funded Warrant, Pre-Funded Warrants to purchase 11,236,631 shares of Class A Common Stock at an exercise price of $0.0001 per share. No cash was paid by DWP in connection with the exercise.
  • F1 Daewoong Co., Ltd. (DWC) owns approximately 52% of the outstanding shares of Daewoong Pharmaceutical Co., Ltd. (DWP), a company organized under the laws of the Republic of Korea, and may be deemed to have voting and dispositive power over, and to beneficially own, the securities of the Issuer held directly by DWP. The securities reported herein are held directly by DWP and are reported by DWC as indirectly beneficially owned, consistent with the Form 3 filed by DWC with respect to the Issuer on January 29, 2026. DWC disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein, and the filing of this statement shall not be deemed an admission that DWC is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
Open filing 0001213900-26-117865 Read from the filing’s XML Dispute this row
2026-10-30 Filed 2026-11-10Daewoong Co., Ltd 10% owner
J

Other acquisition or disposition (describe transaction)

Class A Common Stock, $0.0001 par value per share
Disposed (D)3,8220.294
1,123.668

Derived: shares × price per share. Exact value 1123.668.

23,184,523Indirect (I) By Daewoong Pharmaceutical Co., Ltd.No
F3, F1
  • F3 Represents 3,822 shares of Class A Common Stock withheld by the Issuer in satisfaction of the aggregate exercise price of the Pre-Funded Warrants in accordance with the net exercise formula set forth in the Pre-Funded Warrant, based on the closing sale price of $0.294 per share on October 29, 2026, the trading day immediately preceding the Exercise Date. As a result of the cashless exercise, 11,232,809 shares of Class A Common Stock were issued to DWP.
  • F1 Daewoong Co., Ltd. (DWC) owns approximately 52% of the outstanding shares of Daewoong Pharmaceutical Co., Ltd. (DWP), a company organized under the laws of the Republic of Korea, and may be deemed to have voting and dispositive power over, and to beneficially own, the securities of the Issuer held directly by DWP. The securities reported herein are held directly by DWP and are reported by DWC as indirectly beneficially owned, consistent with the Form 3 filed by DWC with respect to the Issuer on January 29, 2026. DWC disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein, and the filing of this statement shall not be deemed an admission that DWC is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
Open filing 0001213900-26-117865 Read from the filing’s XML Dispute this row
2026-10-30 Filed 2026-11-10Daewoong Co., Ltd 10% owner
X

Exercise of in-the-money or at-the-money derivative security

Derivative security: Pre-Funded Warrant (right to buy) — underlying Class A Common Stock (11,236,631) — exercise price 0.0001
Disposed (D)11,236,6310—0Indirect (I) By Daewoong Pharmaceutical Co., Ltd.No
F2, F4, F1
  • F2 On October 30, 2026 (the Exercise Date), DWP exercised in full, on a cashless basis pursuant to Section 10 of the Pre-Funded Warrant, Pre-Funded Warrants to purchase 11,236,631 shares of Class A Common Stock at an exercise price of $0.0001 per share. No cash was paid by DWP in connection with the exercise.
  • F4 The Pre-Funded Warrants were exercisable at any time on or after January 21, 2026 and did not expire until exercised in full. Following the exercise described in footnotes (2) and (3), no Pre-Funded Warrants remain outstanding.
  • F1 Daewoong Co., Ltd. (DWC) owns approximately 52% of the outstanding shares of Daewoong Pharmaceutical Co., Ltd. (DWP), a company organized under the laws of the Republic of Korea, and may be deemed to have voting and dispositive power over, and to beneficially own, the securities of the Issuer held directly by DWP. The securities reported herein are held directly by DWP and are reported by DWC as indirectly beneficially owned, consistent with the Form 3 filed by DWC with respect to the Issuer on January 29, 2026. DWC disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein, and the filing of this statement shall not be deemed an admission that DWC is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
Open filing 0001213900-26-117865 Read from the filing’s XML Dispute this row
2026-08-19 Filed 2026-08-21LYNCH TIMOTHY P 10% owner
P

Open market or private purchase of non-derivative or derivative security

Class A Common Stock
Acquired (A)1,150,0000.2117
243,455

Derived: shares × price per share. Exact value 243455.0000.

6,500,000Direct (D) No
F1
  • F1 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.1975 to $0.2164 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
Open filing 0000935836-26-000440 Read from the filing’s XML Dispute this row
2026-06-17 Filed 2026-06-22Carter Eric G Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Class A Common Stock
Acquired (A)222,6840—258,705Direct (D) No
F1
  • F1 Represents an award of restricted stock units (RSUs) granted on June 17, 2026 (the Grant Date). The RSUs vest in full on the earlier to occur of (i) the one (1) year anniversary of the Grant Date and (ii) the date of the 2027 annual meeting of the Company's stockholders, subject to continued service through the applicable vesting date.
Open filing 0001104659-26-076509 Read from the filing’s XML Dispute this row
2026-06-17 Filed 2026-06-22Forth Marc Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Class A Common Stock
Acquired (A)222,6840—973,231Direct (D) No
F1
  • F1 Represents an award of restricted stock units (RSUs) granted on June 17, 2026 (the Grant Date). The RSUs vest in full on the earlier to occur of (i) the one (1) year anniversary of the Grant Date and (ii) the date of the 2027 annual meeting of the Company's stockholders, subject to continued service through the applicable vesting date.
Open filing 0001104659-26-076511 Read from the filing’s XML Dispute this row
2026-06-17 Filed 2026-06-22FISCHER JOST Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Class A Common Stock
Acquired (A)222,6840—489,469Direct (D) No
F1
  • F1 Represents an award of restricted stock units (RSUs) granted on June 17, 2026 (the Grant Date). The RSUs vest in full on the earlier to occur of (i) the one (1) year anniversary of the Grant Date and (ii) the date of the 2027 annual meeting of the Company's stockholders, subject to continued service through the applicable vesting date.
Open filing 0001104659-26-076510 Read from the filing’s XML Dispute this row
2026-06-17 Filed 2026-06-22Thunen Shelley B Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Class A Common Stock
Acquired (A)222,6840—258,705Direct (D) No
F1
  • F1 Represents an award of restricted stock units (RSUs) granted on June 17, 2026 (the Grant Date). The RSUs vest in full on the earlier to occur of (i) the one (1) year anniversary of the Grant Date and (ii) the date of the 2027 annual meeting of the Company's stockholders, subject to continued service through the applicable vesting date.
Open filing 0001104659-26-076515 Read from the filing’s XML Dispute this row
2026-06-17 Filed 2026-06-22PALMISANO ROBERT J Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Class A Common Stock
Acquired (A)222,6840—258,705Direct (D) No
F1
  • F1 Represents an award of restricted stock units (RSUs) granted on June 17, 2026 (the Grant Date). The RSUs vest in full on the earlier to occur of (i) the one (1) year anniversary of the Grant Date and (ii) the date of the 2027 annual meeting of the Company's stockholders, subject to continued service through the applicable vesting date.
Open filing 0001104659-26-076513 Read from the filing’s XML Dispute this row
2026-04-02 Filed 2026-04-03Bencich John Officer: CHIEF FINANCIAL OFFICER
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Class A Common Stock
Acquired (A)754,7170—754,717Direct (D) No
F1
  • F1 Represents an award of restricted stock units granted on April 1, 2026 (the Grant Date), which vest in substantially equal installments on each of the first, second, third and fourth anniversary of the Grant Date, subject to continued service through the applicable vesting date.
Open filing 0001104659-26-039697 Read from the filing’s XML Dispute this row
2026-03-04 Filed 2026-03-11Oh Chad Officer: CHIEF MEDICAL OFFICER
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Class A Common Stock
Acquired (A)1,316,8720—2,183,436Direct (D) No
F2
  • F2 Represents outstanding cash-settled restricted stock units granted on May 21, 2025 (the Grant Date) that were modified on March 4, 2026 to be settled in stock instead of cash upon vesting. The restricted stock units continue to vest in substantially equal installments on each of the first, second, third and fourth anniversary of the Grant Date, subject to continued service through the applicable vesting date. The restricted stock units were originally reported in Table II on a Form 4 filed on May 23, 2025.
Open filing 0001104659-26-026550 Read from the filing’s XML Dispute this row
2026-03-04 Filed 2026-03-05Sy Jennifer Officer: PRINCIPAL ACCOUNTING OFFICER
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Class A Common Stock
Acquired (A)925,9250—1,501,176Direct (D) No
F2
  • F2 Represents outstanding cash-settled restricted stock units granted on May 21, 2025 (the Grant Date) that were modified on March 4, 2026 to be settled in stock instead of cash upon vesting. The restricted stock units continue to vest in substantially equal installments on each of the first, second, third and fourth anniversary of the Grant Date, subject to continued service through the applicable vesting date. The restricted stock units were originally reported in Table II on a Form 4 filed on May 23, 2025.
Open filing 0001104659-26-024231 Read from the filing’s XML Dispute this row
2026-03-04 Filed 2026-03-05Wilson Alexander Blair Officer: CLO, CSO, and Corp Secretary
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Class A Common Stock
Acquired (A)1,316,8720—2,183,005Direct (D) No
F2
  • F2 Represents outstanding cash-settled restricted stock units granted on May 21, 2025 (the Grant Date) that were modified on March 4, 2026 to be settled in stock instead of cash upon vesting. The restricted stock units continue to vest in substantially equal installments on each of the first, second, third and fourth anniversary of the Grant Date, subject to continued service through the applicable vesting date. The restricted stock units were originally reported in Table II on a Form 4 filed on May 23, 2025.
Open filing 0001104659-26-024233 Read from the filing’s XML Dispute this row
2026-02-17 Filed 2026-03-11Oh Chad Officer: CHIEF MEDICAL OFFICER
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Class A Common Stock
Acquired (A)862,5000—866,564Direct (D) No
F1
  • F1 Represents an award of restricted stock units granted on February 17, 2026 (the Grant Date), which vest in substantially equal installments on each of the first, second, third and fourth anniversary of the Grant Date, subject to continued service through the applicable vesting date.
Open filing 0001104659-26-026550 Read from the filing’s XML Dispute this row
2026-02-17 Filed 2026-03-05Sy Jennifer Officer: PRINCIPAL ACCOUNTING OFFICER
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Class A Common Stock
Acquired (A)575,0000—575,251Direct (D) No
F1
  • F1 Represents an award of restricted stock units granted on February 17, 2026 (the Grant Date), which vest in substantially equal installments on each of the first, second, third and fourth anniversary of the Grant Date, subject to continued service through the applicable vesting date.
Open filing 0001104659-26-024231 Read from the filing’s XML Dispute this row
2026-02-17 Filed 2026-03-05Wilson Alexander Blair Officer: CLO, CSO, and Corp Secretary
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Class A Common Stock
Acquired (A)862,5000—866,133Direct (D) No
F1
  • F1 Represents an award of restricted stock units granted on February 17, 2026 (the Grant Date), which vest in substantially equal installments on each of the first, second, third and fourth anniversary of the Grant Date, subject to continued service through the applicable vesting date.
Open filing 0001104659-26-024233 Read from the filing’s XML Dispute this row
2026-02-17 Filed 2026-02-19Bancroft Robert E. Director · Officer: PRESIDENT CEO
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Class A Common Stock
Acquired (A)3,000,0000—3,177,103Direct (D) No
F1
  • F1 Represents an award of restricted stock units granted on February 17, 2026 (the Grant Date), which vest in substantially equal installments on each of the first, second, third and fourth anniversary of the Grant Date, subject to continued service through the applicable vesting date.
Open filing 0001104659-26-017726 Read from the filing’s XML Dispute this row

Institutional holders (Form 13F)

Quarter ending 2026-09-30: 7,211 filings read, the latest filed 2026-11-13. Prior quarter ending 2026-06-30: 9,150 filings read.

Showing 1–21 of 21

Institutional holders, largest position first, as filed
ManagerShares or principalValue as filedChange from the prior quarterSource
Nantahala Capital Management, LLC 4,400,000 SH1,297,780 dollarsNot in the prior quarter’s filings read Open filing 0001104659-26-127125 Filed 2026-11-13 Dispute this row
Stonepine Capital Management, LLC 2,125,748 SH637,724 dollarsNot in the prior quarter’s filings read Open filing 0001440771-26-000027 Filed 2026-11-13 Dispute this row
DG Capital Management, LLC 259,146 SH77,744 dollarsNot in the prior quarter’s filings read Open filing 0001512716-26-000017 Filed 2026-11-12 Dispute this row
JANE STREET GROUP, LLC Partly reported under another manager249,762 SH74,928 dollarsNot in the prior quarter’s filings read Open filing 0001595888-26-000162 Filed 2026-11-12 Dispute this row
VANGUARD FIDUCIARY TRUST CO 214,725 SH64,418 dollarsHigher by 201,012 Prior quarter: 13,713Open filing 0000933478-26-000017 Filed 2026-11-13 Dispute this row
GEODE CAPITAL MANAGEMENT, LLC Partly reported under another manager95,311 SH28,592 dollarsUnchanged Prior quarter: 95,311Open filing 0001214717-26-000012 Filed 2026-11-06 Dispute this row
VANGUARD CAPITAL MANAGEMENT LLC 90,529 SH27,159 dollarsUnchanged Prior quarter: 90,529Open filing 0002100119-26-001711 Filed 2026-11-13 Dispute this row
Blue Owl Capital Holdings LP Partly reported under another manager42,353 SH12,706 dollarsUnchanged Prior quarter: 42,353Open filing 0001193125-26-459653 Filed 2026-11-13 Dispute this row
Formidable Asset Management, LLC 20,024 SH14,403 dollarsUnchanged Prior quarter: 20,024Open filing 0001592613-26-000009 Filed 2026-11-03 Dispute this row
Beacon Wealthcare LLC Partly reported under another manager12,856 SH3,857 dollarsNot in the prior quarter’s filings read Open filing 0001849336-26-000005 Filed 2026-10-02 Dispute this row
LPL Financial LLC 11,500 SH3,450 dollarsLower by 7 Prior quarter: 11,507Open filing 0001403438-26-000005 Filed 2026-11-06 Dispute this row
BlackRock, Inc. Partly reported under another manager2,834 SH850 dollarsUnchanged Prior quarter: 2,834Open filing 0002012383-26-003985 Filed 2026-11-13 Dispute this row
Steward Partners Investment Advisory, LLC 1,100 SH330 dollarsUnchanged Prior quarter: 1,100Open filing 0001723397-26-000006 Filed 2026-11-13 Dispute this row
WOLFF WIESE MAGANA LLC 567 SH171 dollarsUnchanged Prior quarter: 567Open filing 0001832097-26-000005 Filed 2026-10-15 Dispute this row
SBI Securities Co., Ltd. 329 SH99 dollarsHigher by 97 Prior quarter: 232Open filing 0001851815-26-000004 Filed 2026-10-22 Dispute this row
DUPONT CAPITAL MANAGEMENT CORP 170 SH51 dollarsUnchanged Prior quarter: 170Open filing 0001140361-26-040602 Filed 2026-10-23 Dispute this row
MORGAN STANLEY Partly reported under another manager150 SH45 dollarsUnchanged Prior quarter: 150Open filing 0000895421-26-000309 Filed 2026-11-13 Dispute this row
GHP Investment Advisors, Inc. 95 SH29 dollarsUnchanged Prior quarter: 95Open filing 0001140361-26-039674 Filed 2026-10-15 Dispute this row
BARCLAYS PLC Partly reported under another manager1 SH0 dollarsLower by 58 Prior quarter: 59Open filing 0000312069-26-000241 Filed 2026-11-06 Dispute this row
Caitong International Asset Management Co., Ltd 1 SH0 dollarsUnchanged Prior quarter: 1Open filing 0001628280-26-068135 Filed 2026-10-29 Dispute this row
DANSKE BANK A/S 1 SH0 dollarsUnchanged Prior quarter: 1Open filing 0001104659-26-124081 Filed 2026-11-09 Dispute this row
Managers in the prior quarter with no filing read for the latest

They may simply not have filed yet: absent from the latest quarter’s filings read is not the same as a position sold.

  • Dauntless Investment Group, LLC 12,490,154 SH
  • StoneX Group Inc. 18,953 SH
  • CITIGROUP INC 7,315 SH
  • UBS Group AG 5,062 SH
  • Tower Research Capital LLC (TRC) 2,567 SH
  • WELLS FARGO COMPANY/MN 90 SH
  • MERCER GLOBAL ADVISORS INC /ADV 80 SH
  • Form 13F covers long positions in Section 13(f) securities only: no short positions and no securities outside that list.
  • A manager that has not yet filed for the latest quarter is absent, not at zero; filings are due up to 45 days after quarter end.
  • A change is the difference between two quarter-end snapshots, not a trade.
  • A position reported under another manager may also appear in that manager’s filing; rows are not added together.
  • Holdings the securities list cannot place with this company, or places ambiguously, are not shown.

5% holders (Schedule 13D and 13G)

Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.

5% holders, newest event first, as filed
HolderPercent of classShares heldEvent dateFormSource
Daewoong Co., Ltd. Class A Common Stock, $0.0001 par value per share30.623,242,546.0010/30/2026 Filed 2026-11-10SCHEDULE 13D/AAmendment 1Open filing 0001213900-26-117881 Dispute this row
Daewoong Pharmaceutical Co., Ltd. Class A Common Stock, $0.0001 par value per share30.523,184,523.0010/30/2026 Filed 2026-11-10SCHEDULE 13D/AAmendment 1Open filing 0001213900-26-117881 Dispute this row
Nantahala Capital Management, LLC Class A common stock, $0.0001 par value per share9.995,048,027.0009/30/2026 Filed 2026-11-13SCHEDULE 13GOpen filing 0001104659-26-127174 Dispute this row
Wilmot B. Harkey Class A common stock, $0.0001 par value per share9.995,048,027.0009/30/2026 Filed 2026-11-13SCHEDULE 13GOpen filing 0001104659-26-127174 Dispute this row
Daniel Mack Class A common stock, $0.0001 par value per share9.995,048,027.0009/30/2026 Filed 2026-11-13SCHEDULE 13GOpen filing 0001104659-26-127174 Dispute this row
Timothy P. Lynch Class A Common Stock13.06,500,00008/19/2026 Filed 2026-08-21SCHEDULE 13GOpen filing 0000935836-26-000442 Dispute this row
Stonepine Capital Management, LLC Class A Common Stock9.96,892,682.0007/15/2026 Filed 2026-07-21SCHEDULE 13GOpen filing 0001440771-26-000012 Dispute this row
Stonepine Capital, L.P. Class A Common Stock9.96,892,682.0007/15/2026 Filed 2026-07-21SCHEDULE 13GOpen filing 0001440771-26-000012 Dispute this row
Stonepine GP, LLC Class A Common Stock9.96,892,682.0007/15/2026 Filed 2026-07-21SCHEDULE 13GOpen filing 0001440771-26-000012 Dispute this row
Jon M. Plexico Class A Common Stock9.96,892,682.0007/15/2026 Filed 2026-07-21SCHEDULE 13GOpen filing 0001440771-26-000012 Dispute this row
Daewoong Co.,Ltd. ("DWC") Common Stock, $0.0001 par value per share49.9912,009,737.0001/21/2026 Filed 2026-01-29SCHEDULE 13DOpen filing 0001213900-26-009802 Dispute this row
Daewoong Pharmaceutical Co. Ltd ("DWP") Common Stock, $0.0001 par value per share49.7512,009,737.0001/21/2026 Filed 2026-01-29SCHEDULE 13DOpen filing 0001213900-26-009802 Dispute this row
Alta Partners LLC Common Stock2.1249,870.0009/30/2025 Filed 2025-10-14SCHEDULE 13G/AAmendment 2Open filing 0001896206-25-000007 Dispute this row
Alta Partners LLC Common Stock5.1586,335.0006/30/2025 Filed 2025-07-09SCHEDULE 13G/AAmendment 1Open filing 0002022308-25-000002 Dispute this row
Daewoong Co.,Ltd. ("DWC") Common Stock, $0.0001 par value per share0.991,357.0003/24/2025 Filed 2026-01-29SCHEDULE 13D/AAmendment 1Open filing 0001213900-26-009785 Dispute this row
Daewoong Pharmaceutical Co. Ltd ("DWP") Common Stock, $0.0001 par value per share0.333,334.0003/24/2025 Filed 2026-01-29SCHEDULE 13D/AAmendment 1Open filing 0001213900-26-009785 Dispute this row

Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.

What was read

2,092,408 filings read, dated 2004-06-14 to 2026-11-13: Forms 3, 3/A, 4, 4/A, 5, 5/A.

Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.

Filings read, by filing year
Filing yearFilings read
20151
2016204,322
2017202,494
2018202,048
2019193,638
2020144,184
2021224,474
202240,015
2023199,811
2024185,386
2025235,520
2026254,737

Filings made before the SEC required XML are listed, not extracted.

Back to AEON Biopharma, Inc.